{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:11:43Z","timestamp":1787897503281,"version":"build-2784847793"},"reference-count":54,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003033","name":"Ministerio de Ciencia, Tecnolog\u00eda e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["902-2019"],"award-info":[{"award-number":["902-2019"]}],"id":[{"id":"10.13039\/501100003033","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,1,28]]},"published-print":{"date-parts":[[2025,3]]},"abstract":"\n Objective<\/jats:title>\n To determine the cost-effectiveness of the QuantiFERON (QFT) test versus the tuberculin skin test (TST) in diagnosing latent tuberculosis infection (LTBI) in immunocompetent children under 15 years of age who are in contact with active tuberculosis (TB) patients in the context of the Colombian healthcare system.<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n Health economic evaluation. Decision tree over a horizon of <1 year.<\/jats:p>\n <\/jats:sec>\n \n Setting<\/jats:title>\n From the perspective of the Colombian healthcare system, the direct healthcare costs related to tests were considered, and diagnostic performance was used as a measure of effectiveness. The currency was the US dollar (US$) for the year 2022, with a cost-effectiveness threshold of US$6666.<\/jats:p>\n <\/jats:sec>\n \n Participants<\/jats:title>\n A simulated hypothetical cohort of 2000 immunocompetent children under 15 years of age who are in contact with active TB patients and were vaccinated with BCG at birth.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n QFT test and TST to detect LTBI.<\/jats:p>\n <\/jats:sec>\n \n Primary outcome measure<\/jats:title>\n The incremental cost-effectiveness ratio (ICER) was estimated, and univariate deterministic and probabilistic sensitivity analyses were conducted using 5000 simulations.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n QFT was found to be cost-effective with an ICER of US$705 for each correctly diagnosed case. In the one-way deterministic sensitivity analysis, QFT remained cost-effective across nearly all proposed scenarios; however, the QFT was considered \u2018potentially cost-effective\u2019 when TST specificity reached its highest value. The ICER was unaffected by variations in LTBI prevalence. In the probabilistic sensitivity analysis, QFT was cost-effective in 85.06% of the simulated scenarios, while TST was dominant in 11.8%.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This study provides evidence of the cost-effectiveness of QFT compared with TST in diagnosing LTBI among immunocompetent children under 15 years who have been in contact with active TB patients in the Colombian context.<\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-087333","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T16:40:13Z","timestamp":1741884013000},"page":"e087333","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-effectiveness analysis comparing QuantiFERON test and tuberculin skin test for the diagnosis of latent tuberculosis infection in immunocompetent children under 15 years of age in Colombia"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0532-6301","authenticated-orcid":false,"given":"Cristian Eduardo","family":"Navarro","sequence":"first","affiliation":[{"name":"Facultad de Medicina, Universidad de Antioquia, Medellin, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4004-2219","authenticated-orcid":false,"given":"Dione","family":"Benjumea-Bedoya","sequence":"additional","affiliation":[{"name":"Unidad de Bacteriolog\u00eda y Micobacterias, Corporacion para Investigaciones Biologicas - CIB, Medellin, Colombia"},{"name":"Grupo de Investigaci\u00f3n en Salud Familiar y Comunitaria, Facultad de Ciencias de la Salud, Corporaci\u00f3n Universitaria Remington, Medellin, Colombia"},{"name":"Grupo de Epidemiolog\u00eda, Facultad Nacional de Salud P\u00fablica, Universidad de Antioquia, Medellin, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3872-0428","authenticated-orcid":false,"given":"Andres Felipe","family":"Estupinan-Bohorquez","sequence":"additional","affiliation":[{"name":"Grupo de Investigaci\u00f3n en Salud Familiar y Comunitaria, Facultad de Ciencias de la Salud, Corporaci\u00f3n Universitaria Remington, Medellin, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0751-8932","authenticated-orcid":false,"given":"Ivan D","family":"Florez","sequence":"additional","affiliation":[{"name":"Departamento de Pediatr\u00eda, Universidad de Antioquia, Medellin, Colombia"},{"name":"School of Rehabilitation Science, McMaster University, Hamilton, Ontario, Canada"},{"name":"Pediatric Intensive Care Unit, Cl\u00ednica Las Am\u00e9ricas-AUNA, Medellin, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"2025121602325199000_15.3.e087333.1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00120908"},{"key":"2025121602325199000_15.3.e087333.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1405427"},{"key":"2025121602325199000_15.3.e087333.3","first-page":"1192","article-title":"False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?","volume":"10","author":"Farhat","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025121602325199000_15.3.e087333.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2013.07.008"},{"key":"2025121602325199000_15.3.e087333.5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/occmed\/kqw035","article-title":"Tuberculin and QuantiFERON-TB-Gold tests for latent tuberculosis: a meta-analysis","volume":"66","author":"Doosti-Irani","year":"2016","journal-title":"OCCMED"},{"key":"2025121602325199000_15.3.e087333.6","first-page":"445","article-title":"Concordance between the test of the tuberculin and Interferon Gamma Release Assay-IGRA in patients with immune-mediated inflammatory diseases","volume":"32","author":"P\u00e9rez Catal\u00e1n","year":"2019","journal-title":"Rev Esp Quimioter"},{"key":"2025121602325199000_15.3.e087333.7","unstructured":"Ministerio de Salud y Protecci\u00f3n Social . Resoluci\u00f3n 227 de 2020. 2020.1\u2013175. Available: https:\/\/www.minsalud.gov.co\/Normatividad_Nuevo\/Resoluci\u00f3n"},{"key":"2025121602325199000_15.3.e087333.8","unstructured":"Ministerio de Salud y Protecci\u00f3n Social . Informe de evento tuberculosis a\u00f1o 2022. 2022.1\u201381."},{"key":"2025121602325199000_15.3.e087333.9","unstructured":"Ministerio de Salud y Protecci\u00f3n Social . Indicadores b\u00e1sicos de salud 2021. 2021.1\u201395. Available: https:\/\/www.minsalud.gov.co\/sites\/rid\/Lists\/BibliotecaDigital\/RIDE\/VS\/ED\/GCFI\/indicadores-basicos-salud-2021.pdf"},{"key":"2025121602325199000_15.3.e087333.10","unstructured":"National Society of Tuberculosis Clinicians, National Tuberculosis Controllers Association . Testing and treatment of latent tuberculosis infection in the United States: clinical recommendations. National Society of Tuberculosis Clinicians; 2021.1\u2013132."},{"key":"2025121602325199000_15.3.e087333.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2008.02.011"},{"key":"2025121602325199000_15.3.e087333.12","unstructured":"Qiagen . QuantiFERON-TB gold plus (QFT-plus) elisa package insert. 2018.1\u201340."},{"key":"2025121602325199000_15.3.e087333.13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.15381\/anales.v78i1.13019","article-title":"Costos de bolsillo de pacientes con diagn\u00f3stico de Tuberculosis en Colombia","volume":"78","author":"Mart\u00ednez-S\u00e1nchez","year":"2017","journal-title":"An Fac med"},{"key":"2025121602325199000_15.3.e087333.14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.vhri.2023.11.010","article-title":"Cost-Effectiveness Analysis Comparing QuantiFERON-TB Gold Plus Test and Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Immunocompetent Subjects in Colombia","volume":"41","author":"Navarro","year":"2024","journal-title":"Value Health Reg Issues"},{"key":"2025121602325199000_15.3.e087333.15","unstructured":"Mabel MV , Aurelio MM , HEduardo CJ . Manual for the preparation of economic evaluations in health. Institute for Health Technology Assessment; 2014.1\u201336. Available: https:\/\/www.iets.org.co\/Archivos\/64\/Manual_evaluacion_economica.pdf"},{"key":"2025121602325199000_15.3.e087333.16","unstructured":"Faria R , Mej\u00eda Mej\u00eda A . Technical documents to support the construction of the Colombian reference case for economic evaluation in health. Institute for Health Technology Assessment; 2014.1\u201391. Available: https:\/\/www.iets.org.co\/2014\/11\/24\/documentos-tecnicos-de-apoyo-a-la-construccion-del-caso-de-referencia-colombiano-para-la-evaluacion-economica-en-salud\/"},{"key":"2025121602325199000_15.3.e087333.17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.10357"},{"key":"2025121602325199000_15.3.e087333.18","doi-asserted-by":"publisher","DOI":"10.3310\/hta22440"},{"key":"2025121602325199000_15.3.e087333.19","unstructured":"Centers for Disease Control and Prevention . Vaccine recommendations and guidelines of the ACIP. 2024. Available: https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/immunocompetence.html"},{"key":"2025121602325199000_15.3.e087333.20","unstructured":"Direcci\u00f3n de Regulaci\u00f3n de Beneficios Costos y Tarifas del Aseguramiento en Salud . Estudio de suficiencia y de los mecanismos de ajuste del riesgo para el c\u00e1lculo de la Unidad de Pago por Capitaci\u00f3n del a\u00f1o 2021. 2021. Available: https:\/\/www.minsalud.gov.co\/salud\/POS\/Paginas\/unidad-de-pago-por-capitacion-upc.aspx"},{"key":"2025121602325199000_15.3.e087333.21","unstructured":"Ministerio de Salud y Protecci\u00f3n Social . Aplicaci\u00f3n de la metodolog\u00eda para la definici\u00f3n del presupuesto m\u00e1ximo a transferir a las Entidades Promotoras de Salud de los reg\u00edmenes Contributivo y Subsidiado y a las entidades obligadas a compensar - EOC en la vigencia 2020. 2020.1\u20131353. Available: https:\/\/www.minsalud.gov.co\/sites\/rid\/Lists\/BibliotecaDigital\/RIDE\/VP\/RBC\/documento-tecnico-presupuesto-maximo.pdf"},{"key":"2025121602325199000_15.3.e087333.22","unstructured":"Ministry of Health and Social Protection . Drug Price Information System (SISMED). 2024. Available: https:\/\/www.sispro.gov.co\/central-prestadores-de-servicios\/Pages\/SISMED-Sistema-de-Informacion-de-Precios-de-Medicamentos.aspx"},{"key":"2025121602325199000_15.3.e087333.23","unstructured":"National Administrative Department of Statistics (DANE) . Consumer price index. 2024. Available: https:\/\/www.dane.gov.co\/index.php\/estadisticas-por-tema\/precios-y-costos\/indice-de-precios-al-consumidor-ipc"},{"key":"2025121602325199000_15.3.e087333.24","unstructured":"Estupi\u00f1\u00e1n-Bohorquez AF , Benjumea-Bedoya D , Florez ID . Accuracy of IGRA and TST for the diagnosis of latent tuberculosis infection in children: a systematic review and metanalysis. PROSPERO 2022. Available: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42022354984"},{"key":"2025121602325199000_15.3.e087333.25","unstructured":"Institute for Health Metrics and Evaluation . Global burden of disease study. 2019. Available: https:\/\/vizhub.healthdata.org\/gbd-compare\/"},{"key":"2025121602325199000_15.3.e087333.26","unstructured":"Central Bank of Colombia . Gross domestic product (GDP). 2023. Available: https:\/\/www.banrep.gov.co\/es\/estadisticas\/producto-interno-bruto-pib"},{"key":"2025121602325199000_15.3.e087333.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.05.029"},{"key":"2025121602325199000_15.3.e087333.28","unstructured":"Trikalinos TA , Dahabreh IJ , Lee J , et al . Defining an optimal format for presenting research needs. Agency for Healthcare Research and Quality; 2011.1\u201343."},{"key":"2025121602325199000_15.3.e087333.29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/08870446.2014.953532","article-title":"Risk of bias in trial-based economic evaluations: identification of sources and bias-reducing strategies","volume":"30","author":"Evers","year":"2015","journal-title":"Psychol Health"},{"key":"2025121602325199000_15.3.e087333.30","unstructured":"Organizaci\u00f3n Mundial de la Salud . Directrices sobre la atenci\u00f3n de la infecci\u00f3n tuberculosa latente. 2015.1\u201340."},{"key":"2025121602325199000_15.3.e087333.31","unstructured":"World Health Organization . Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva World Health Organization; 2018.1\u201378."},{"key":"2025121602325199000_15.3.e087333.32","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2022-219085"},{"key":"2025121602325199000_15.3.e087333.33","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-200933"},{"key":"2025121602325199000_15.3.e087333.34","doi-asserted-by":"publisher","DOI":"10.3310\/hta20220"},{"key":"2025121602325199000_15.3.e087333.35","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs479"},{"key":"2025121602325199000_15.3.e087333.36","doi-asserted-by":"crossref","first-page":"294963","DOI":"10.1155\/2014\/294963","article-title":"Added value of QuantiFERON TB-Gold in-Tube for detecting latent tuberculosis infection among persons living with HIV\/AIDS","volume":"2014","author":"Souza","year":"2014","journal-title":"Biomed Res Int"},{"key":"2025121602325199000_15.3.e087333.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2013.08.009"},{"key":"2025121602325199000_15.3.e087333.38","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jinf.2018.07.003","article-title":"Interferon-gamma release assay for tuberculosis screening of solid-organ transplant recipients is cost-effective","volume":"78","author":"Kowada","year":"2019","journal-title":"J Infect"},{"key":"2025121602325199000_15.3.e087333.39","doi-asserted-by":"publisher","DOI":"10.1111\/phn.12083"},{"key":"2025121602325199000_15.3.e087333.40","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-201542"},{"key":"2025121602325199000_15.3.e087333.41","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-29648-z","article-title":"A cost-effectiveness evaluation of latent tuberculosis infection screening of a migrant population in Malaysia","volume":"13","author":"Barker","year":"2023","journal-title":"Sci Rep"},{"key":"2025121602325199000_15.3.e087333.42","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2008.524"},{"key":"2025121602325199000_15.3.e087333.43","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1086\/668436","article-title":"Cost-effectiveness of different screening strategies (single or dual) for the diagnosis of tuberculosis infection in healthcare workers","volume":"33","author":"del Campo","year":"2012","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2025121602325199000_15.3.e087333.44","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jhin.2014.10.002","article-title":"Cost-effectiveness of interferon-gamma release assay for systematic tuberculosis screening of healthcare workers in low-incidence countries","volume":"89","author":"Kowada","year":"2015","journal-title":"J Hosp Infect"},{"key":"2025121602325199000_15.3.e087333.45","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4103\/2212-5531.201899","article-title":"Comparison of cost-effectiveness between the quantiFERON-TB Gold-In-Tube and T-Spot tests for screening health-care workers for latent tuberculosis infection","volume":"6","author":"Mukai","year":"2017","journal-title":"Int J Mycobacteriol"},{"key":"2025121602325199000_15.3.e087333.46","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-017-0865-x","article-title":"Revisiting annual screening for latent tuberculosis infection in healthcare workers: a cost-effectiveness analysis","volume":"15","author":"Mullie","year":"2017","journal-title":"BMC Med"},{"key":"2025121602325199000_15.3.e087333.47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225197","article-title":"Cost-effectiveness of QuantiFERON-TB Gold In-Tube versus tuberculin skin test for diagnosis and treatment of Latent Tuberculosis Infection in primary health care workers in Brazil","volume":"14","author":"Loureiro","year":"2019","journal-title":"PLoS One"},{"key":"2025121602325199000_15.3.e087333.48","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph17051697","article-title":"Cost-Effectiveness of Annual Screening for Tuberculosis among Italian Healthcare Workers: A Retrospective Study","volume":"17","author":"Coppeta","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"2025121602325199000_15.3.e087333.49","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-2728"},{"key":"2025121602325199000_15.3.e087333.50","first-page":"1414","article-title":"Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts","volume":"12","author":"Marra","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025121602325199000_15.3.e087333.51","first-page":"471","article-title":"Cost-effectiveness of QuantiFERON-TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection","volume":"14","author":"Deuffic-Burban","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025121602325199000_15.3.e087333.52","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2466-10-7","article-title":"Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis","volume":"10","author":"Pooran","year":"2010","journal-title":"BMC Pulm Med"},{"key":"2025121602325199000_15.3.e087333.53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059546","article-title":"Cost-effectiveness of Quantiferon\u00ae-TB Gold-in-Tube versus tuberculin skin testing for contact screening and treatment of latent tuberculosis infection in Brazil","volume":"8","author":"Steffen","year":"2013","journal-title":"PLoS One"},{"key":"2025121602325199000_15.3.e087333.54","article-title":"Screening tests for active pulmonary tuberculosis in children","volume":"6","author":"Vonasek","year":"2021","journal-title":"Cochrane Database Syst Rev"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-087333","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T10:33:03Z","timestamp":1765881183000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-087333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":54,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,13]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1136\/bmjopen-2024-087333"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-087333","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]}}}